The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice

Atherosclerosis Supplements

Volumn 15, Issue 1, 2014, Pages 1-15

  Sattar, Naveed A ^a   Ginsberg, Henry ^b   Ray, Kausik ^c   Chapman, M John ^d   Arca, Marcello ^e   Averna, Maurizio ^f   Betteridge, D John ^g   Bhatnagar, Deepak ^h   Bilianou, Elena ⁱ   Carmena, Rafael ^j   Češka, Richard ^k   Corsini, Alberto ^l   Erbel, Raimund ^m   Flynn, Paul D ⁿ   Garcia Moll, Xavier ^o   Gumprecht, Janusz ^p   Ishibashi, Shun ^q   Jambart, Selim ^r   Kastelein, John J P ^s   Maher, Vincent ^t   Marques da Silva, Pedro ^u   Masana, Luis ^v   Odawara, Masato ^w   Pedersen, Terje R ^x   Rotella, Carlo Maria ^y   Salti, Ibrahim ^z   Teramoto, Tamio ^aa   Tokgozoglu, Lale ^ab   Toth, Peter P ^ac   Valensi, Paul ^ad   Vergès, Bruno ^ae   more..

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f UNIVERSITY OF PALERMO   (Italy)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h ROYAL OLDHAM HOSPITAL   (United Kingdom)

ⁱ TZANEIO GENERAL HOSPITAL OF PIRAEUS   (Greece)

^j UNIVERSITY OF VALENCIA   (Spain)

^k CHARLES UNIVERSITY   (Czech Republic)

^l UNIVERSITY OF MILAN   (Italy)

^m UNIVERSITY OF DUISBURG ESSEN   (Germany)

ⁿ ADDENBROOKE S HOSPITAL   (United Kingdom)

^o HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^p MEDICAL UNIVERSITY OF SILESIA   (Poland)

^q JICHI MEDICAL UNIVERSITY   (Japan)

^r SAINT JOSEPH UNIVERSITY   (Lebanon)

^s UNIVERSITY OF AMSTERDAM   (Netherlands)

^t ADELAIDE AND MEATH HOSPITAL   (Ireland)

^u Universidade de Lisboa   (Portugal)

^v UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^w TOKYO MEDICAL UNIVERSITY   (Japan)

^x ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^y UNIVERSITY OF FLORENCE   (Italy)

^z AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^aa TEIKYO UNIVERSITY   (Japan)

^ab HACETTEPE UNIVERSITY   (Turkey)

^ac UNIVERSITY OF ILLINOIS   (United States)

^ad UNIVERSITÉ PARIS 13   (France)

^ae DIJON UNIVERSITY HOSPITAL   (France)

more..

Author keywords

Cardiovascular; CVD; Diabetes; Diabetogenicity; Statins; T2D

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; CHYLOMICRON; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; STATIN (PROTEIN); VERY LOW DENSITY LIPOPROTEIN; GLYCOSYLATED HEMOGLOBIN; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DIABETOGENESIS; DIET; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; EXERCISE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; RHABDOMYOLYSIS; RISK REDUCTION; SEDENTARY LIFESTYLE; SMOKING CESSATION; WEIGHT REDUCTION; ADULT; BLOOD; CARDIOVASCULAR DISEASES; CASE REPORT; COHORT ANALYSIS; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DIET RESTRICTION; DISEASE PREDISPOSITION; FORECASTING; MALE; META ANALYSIS (TOPIC); MIDDLE AGED; MULTICENTER STUDY (TOPIC); OBSERVATIONAL STUDY; PREDIABETIC STATE; RISK ASSESSMENT; RISK FACTOR; STATISTICS AND NUMERICAL DATA;

ADULT; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; COHORT STUDIES; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DISEASE SUSCEPTIBILITY; FASTING; FORECASTING; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; META-ANALYSIS AS TOPIC; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; OBSERVATIONAL STUDY AS TOPIC; PRACTICE GUIDELINES AS TOPIC; PREDIABETIC STATE; RISK ASSESSMENT; RISK FACTORS;

EID: 84900802536     PISSN: 15675688     EISSN: 18785050     Source Type: Journal    
DOI: 10.1016/j.atherosclerosissup.2014.04.001     Document Type: Article

References (111)

1. Nichols M., Townsend N., Luengo-Fernandex R., et al. European Cardiovascular Disease Statistics 2012, Available at:. http://www.escardio.org/about/what/advocacy/EuroHeart/Pages/2012-CVD-statistics.aspx.
2. Perk J., De B.G., Gohlke H., et al. European guidelines on cardiovascular disease prevention in clinical practice (Version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Int J Behav Med 2012, 19:403-488.
3. Reiner Z., Catapano A.L., De B.G., et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011, 32:1769-1818.
4. Standards of medical care in diabetes-2014. Diabetes Care 2014, 37(Suppl. 1):S14-S80.
5. Mancia G. Total cardiovascular risk: a new treatment concept. J Hypertens Suppl 2006, 24:S17-S24.
6. Cohen J.D., Cziraky M.J., Cai Q., et al. 30-year trends in serum lipids among United States adults: results from the National Health and Nutrition Examination Surveys II, III, and 1999-2006. Am J Cardiol 2010, 106:969-975.
7. Yusuf S., Hawken S., Ounpuu S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937-952.
8. Ryden L., Grant P.J., Anker S.D., et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013, 34:3035-3087.
9. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004, 44:720-732.
10. Reiner Z. Statins in the primary prevention of cardiovascular disease. Nat Rev Cardiol 2013, 10:453-464.
11. Stone N.J., Robinson J., Lichtenstein A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013, Epub ahead of print. Available at:. http://circ.ahajournals.org/content/early/2013/11/11/01.cir.0000437738.63853.7a.long.
12. Kotseva K., Wood D., De B.G., et al. EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries. Eur J Cardiovasc Prev Rehabil 2010, 17:530-540.
13. Nichols M., Townsend N., Scarborough P., et al. Trends in age-specific coronary heart disease mortality in the European Union over three decades: 1980-2009. Eur Heart J 2013, 34:3017-3027.
14. Nordestgaard B.G., Palmer T.M., Benn M., et al. The effect of elevated body mass index on ischemic heart disease risk: causal estimates from a Mendelian randomisation approach. PLoS Med 2012, 9:e1001212.
15. International Diabetes Federation Global guidelines for Type 2 diabetes 2012, Available at:. http://www.idf.org/sites/default/files/IDF%20Guideline%20for%20Type%202%20Diabetes.pdf.
16. Mathers C.D., Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006, 3:e442.
17. Lindstrom J., Neumann A., Sheppard K.E., et al. Take action to prevent diabetes-the IMAGE toolkit for the prevention of type 2 diabetes in Europe. Horm Metab Res 2010, 42(Suppl. 1):S37-S55.
18. O'Donnell M.J., Xavier D., Liu L., et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet 2010, 376:112-123.
19. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
20. Baigent C., Blackwell L., Emberson J., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681.
21. Kearney P.M., Blackwell L., Collins R., et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008, 371:117-125.
22. Mihaylova B., Emberson J., Blackwell L., et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012, 380:581-590.
23. Hsia J., MacFadyen J.G., Monyak J., et al. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). J Am Coll Cardiol 2011, 57:1666-1675.
24. Taylor F., Huffman M.D., Macedo A.F., et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013, 1:CD004816. Available at:. http://www.ncbi.nlm.nih.gov/pubmed/23440795.
25. Nissen S.E., Nicholls S.J., Sipahi I., et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. J Am Med Assoc 2006, 295:1556-1565.
26. Nicholls S.J., Ballantyne C.M., Barter P.J., et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 2011, 365:2078-2087.
27. Alberton M., Wu P., Druyts E., et al. Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis. QJM 2012, 105:145-157.
28. Jones P.H., Davidson M.H., Stein E.A., et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003, 92:152-160.
29. Kashani A., Phillips C.O., Foody J.M., et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 2006, 114:2788-2797.
30. Dale K.M., Coleman C.I., Henyan N.N., et al. Statins and cancer risk: a meta-analysis. J Am Med Assoc 2006, 295:74-80.
31. Muldoon M.F., Barger S.D., Ryan C.M., et al. Effects of lovastatin on cognitive function and psychological well-being. Am J Med 2000, 108:538-546.
32. Nielsen S.F., Nordestgaard B.G., Bojesen S.E. Statin use and reduced cancer-related mortality. N Engl J Med 2012, 367:1792-1802.
33. Hoffman K.B., Kraus C., Dimbil M., et al. A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class. PLoS One 2012, 7:e42866.
34. Merck & Co. Simvastatin (Zocor) Prescribing Information 2013, Available at:. http://www.merck.com/product/usa/pi_circulars/z/zocor/zocor_pi.pdf.
35. Ridker P.M., Pradhan A., MacFadyen J.G., et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012, 380:565-571.
36. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
37. Freeman D.J., Norrie J., Sattar N., et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001, 103:357-362.
38. Preiss D., Seshasai S.R., Welsh P., et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. J Am Med Assoc 2011, 305:2556-2564.
39. Sattar N., Preiss D., Murray H.M., et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010, 375:735-742.
40. Sattar N., Taskinen M.R. Statins are diabetogenic-myth or reality?. Atheroscler Suppl 2012, 13:1-10.
41. Waters D.D., Ho J.E., DeMicco D.A., et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol 2011, 57:1535-1545.
42. Rocco M.B. Statins and diabetes risk: fact, fiction, and clinical implications. Cleve Clin J Med 2012, 79:883-893.
43. Goldstein M.R., Mascitelli L. Do statins cause diabetes?. Curr Diab Rep 2013, 13:381-390.
44. Carter A.A., Gomes T., Camacho X., et al. Risk of incident diabetes among patients treated with statins: population based study. Brit Med J 2013, 346:f2610.
45. Zaharan N.L., Williams D., Bennett K. Statins and risk of treated incident diabetes in a primary care population. Br J Clin Pharmacol 2013, 75:1118-1124.
46. Shepherd J., Blauw G.J., Murphy M.B., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002, 360:1623-1630.
47. Mills E.J., Wu P., Chong G., et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM 2011, 104:109-124.
48. Ray K. Statin diabetogenicity: guidance for clinicians. Cardiovasc Diabetol 2013, 12(Suppl. 1):S3.
49. Taylor K.S., Heneghan C.J., Farmer A.J., et al. All-cause and cardiovascular mortality in middle-aged people with Type 2 diabetes compared with people without diabetes in a large U.K. primary care database. Diabetes Care 2013, 36:2366-2371.
50. Sarwar N., Gao P., Seshasai S.R., et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010, 375:2215-2222.
51. Seshasai S.R., Kaptoge S., Thompson A., et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011, 364:829-841.
52. FDA drug safety communication: important safety label changes to cholesterol-lowering statin drugs 2012, Available from:. http://www.fda.gov/Drugs/DrugSafety/ucm293101.html.
53. Graham I., Atar D., Borch-Johnsen K., et al. European guidelines on cardiovascular disease prevention in clinical practice. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil 2007, 14(Suppl. 2):S1-S113.
54. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
55. Anderson T.J., Gregoire J., Hegele R.A., et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2013, 29:151-167.
56. Di Angelantonio E., Sarwar N., Perry P., et al. Major lipids, apolipoproteins, and risk of vascular disease. J Am Med Assoc 2009, 302:1993-2000.
57. Chapman M.J., Ginsberg H.N., Amarenco P., et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011, 32:1345-1361.
58. Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO consultation. Part 1. Diagnosis and classification of diabetes mellitus 2010, World Health Organisation, Available from:. http://www.who.int/diabetes/publications/en/.
59. World Health Organisation (WHO) Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus 2011, Available at:. http://www.who.int/diabetes/publications/report-hba1c_2011.pdf.
60. Little R.R., Rohlfing C.L., Wiedmeyer H.M., et al. The national glycohemoglobin standardization program: a five-year progress report. Clin Chem 2001, 47:1985-1992.
61. Sattar N. Revisiting the links between glycaemia, diabetes and cardiovascular disease. Diabetologia 2013, 56:686-695.
62. Wannamethee S.G., Shaper A.G., Whincup P.H., et al. Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: Influence of age at onset, diabetes duration, and established and novel risk factors. Arch Intern Med 2011, 171:404-410.
63. Looker H.C., Nyangoma S.O., Cromie D., et al. Diabetic retinopathy at diagnosis of type 2 diabetes in Scotland. Diabetologia 2012, 55:2335-2342.
64. Schwarz P.E., Li J., Lindstrom J., et al. Tools for predicting the risk of type 2 diabetes in daily practice. Horm Metab Res 2009, 41:86-97.
65. Abbasi A., Peelen L.M., Corpeleijn E., et al. Prediction models for risk of developing type 2 diabetes: systematic literature search and independent external validation study. Brit Med J 2012, 345:e5900.
66. Chatterton H., Younger T., Fischer A., et al. Risk identification and interventions to prevent type 2 diabetes in adults at high risk: summary of NICE guidance. Brit Med J 2012, 345:e4624.
67. Knowler W.C., Fowler S.E., Hamman R.F., et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009, 374:1677-1686.
68. Knowler W.C., Barrett-Connor E., Fowler S.E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.
69. Gerstein H.C., Yusuf S., Bosch J., et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006, 368:1096-1105.
70. Pan X.R., Li G.W., Hu Y.H., et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997, 20:537-544.
71. Lindstrom J., Ilanne-Parikka P., Peltonen M., et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006, 368:1673-1679.
72. Eriksson K.F., Lindgarde F. No excess 12-year mortality in men with impaired glucose tolerance who participated in the Malmo Preventive Trial with diet and exercise. Diabetologia 1998, 41:1010-1016.
73. DeFronzo R.A., Tripathy D., Schwenke D.C., et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011, 364:1104-1115.
74. American Diabetes Association Management of dyslipidemia in adults with diabetes. Diabetes Care 2011, 34:S12-S47.
75. Ray K.K., Seshasai S.R., Wijesuriya S., et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009, 373:1765-1772.
76. Preiss D., Lloyd S.M., Ford I., et al. Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. Lancet Diabetes Endocrinol 2013, 10.1016/S2213-8587(13)70152-9.
77. Saremi A., Schwenke D.C., Buchanan T.A., et al. Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. Arterioscler Thromb Vasc Biol 2013, 33:393-399.
78. Waters D.D., Ho J.E., Boekholdt S.M., et al. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. J Am Coll Cardiol 2013, 61:148-152.
79. Watts G.F., Ooi E.M. Balancing the cardiometabolic benefits and risks of statins. Lancet 2012, 380:541-543.
80. Betteridge D.J., Gibson J.M. Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes. Diabet Med 2007, 24:541-549.
81. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364:685-696.
82. Koh K.K., Quon M.J., Han S.H., et al. Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J Am Coll Cardiol 2010, 55:1209-1216.
83. Sabatine M.S., Wiviott S.D., Morrow D.A., et al. High-dose atorvastatin associated with worse glycemic control: a PROVE-IT TIMI 22 substudy. Circulation 2004, 110(Suppl. 3):834.
84. Yokote K., Saito Y. Influence of statins on glucose tolerance in patients with type 2 diabetes mellitus: subanalysis of the collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). J Atheroscler Thromb 2009, 16:297-298.
85. Teramoto T., Shimano H., Yokote K., et al. New evidence on pitavastatin: efficacy and safety in clinical studies. Expert Opin Pharmacother 2010, 11:817-828.
86. Teramoto T., Urashima M., Shimano H., et al. A large-scale study on cardio-cerebrovascular events during pitavastatin (LIVALO tablet) therapy in Japanese patients with hypercholesterolemia LIVES 5-year extension study. Jpn Pharmacol Ther 2011, 39:789-803.
87. Saku K., Zhang B., Noda K. Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial. Circ J 2011, 75:1493-1505.
88. Sponseller C.A., Morgan R.E., Campbell S.E. Pitavastatin 4 mg significantly reduces LDL-P and increases HDL size compared with pravastatin 40 mg (PREVAIL US). J Clin Lipidol 2012, 6:288-289.
89. Chapman M.J., Orsoni A., Robillard P., et al. Effect of high-dose pitavastatin on glucose homeostasis in patients at elevated risk of new-onset diabetes: insights from the CAPITAIN and PREVAIL-US studies. Curr Med Res Opin 2014, 10.1185/03007995.2013.874989.
90. Bellia A., Rizza S., Lombardo M.F., et al. Deterioration of glucose homeostasis in type 2 diabetic patients one year after beginning of statins therapy. Atherosclerosis 2012, 223:197-203.
91. Baker W.L., Talati R., White C.M., et al. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract 2010, 87:98-107.
92. Navarese E.P., Buffon A., Andreotti F., et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol 2013, 111:1123-1130.
93. Odawara M., Yamazaki T., Kishimoto J., et al. Pitavastatin for the delay or prevention of diabetes development in individuals with impaired glucose tolerance 2013, 73rd American Diabetes Association, Chicago, IL, USA,. Avaialble at:. http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=3217%26sKey=0687e7c8-c97d-442b-92ec-ae505e051854%26cKey=b4ea3c2f-884e-44d3-b9b1-86846eadbd1d%26mKey=%7B89918D6D-3018-4EA9-9D4F-711F98A7AE5D%7D.
94. Kryzhanovski V., Morgan R., Sponseller C.A., Davidson M.H. Pitavastatin 4 mg provides significantly greater reduction in LDL-C compared to pravastatin 40 mg with neutral effects on glucose metabolism: prespecified safety analysis from the short-term phase 4 PREVAIL US trial in patients with primary hyperlipidemia or mixed dyslipidemia. J Am Coll Cardiol 2012, 59:E1692.
95. Kryzhanovski V., Eriksson M., Hounslow N., Sponseller C.A. Short-term and long-term effects of pitavastatin and simvastatin on fasting plasma glucose in patients with primary hyperlipidemia or mixed dyslipidemia and >=2 risk factors for CHD. J Am Coll Cardiol 2012, 59:E1659.
96. Danaei G., Garcia Rodriguez L.A., Fernandez C.O., et al. Statins and risk of diabetes: an analysis of electronic medical records to evaluate possible bias due to differential survival. Diabetes Care 2013, 36:1236-1240.
97. Supale S., Li N., Brun T., et al. Mitochondrial dysfunction in pancreatic beta cells. Trends Endocrinol Metab 2012, 23:477-487.
98. Sampson U.K., Linton M.F., Fazio S. Are statins diabetogenic?. Curr Opin Cardiol 2011, 26:342-347.
99. Koh K.K., Sakuma I., Quon M.J. Differential metabolic effects of distinct statins. Atherosclerosis 2011, 215:1-8.
100. Hoeks J., Schrauwen P. Muscle mitochondria and insulin resistance: a human perspective. Trends Endocrinol Metab 2012, 23:444-450.
101. Kusminski C.M., Scherer P.E. Mitochondrial dysfunction in white adipose tissue. Trends Endocrinol Metab 2012, 23:435-443.
102. Rosenbaum D., Dallongeville J., Sabouret P., et al. Discontinuation of statin therapy due to muscular side effects: a survey in real life. Nutr Metab Cardiovasc Dis 2012, 23:871-875.
103. Draeger A., Monastyrskaya K., Mohaupt M., et al. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol 2006, 210:94-102.
104. Golomb B.A., Evans M.A., Dimsdale J.E., et al. Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial. Arch Intern Med 2012, 172:1180-1182.
105. Liao J.K. Safety and efficacy of statins in Asians. Am J Cardiol 2007, 99:410-414.
106. Culver A.L., Ockene I.S., Balasubramanian R., et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med 2012, 172:144-152.
107. Krumholz H.M., Vaccarino V., Mendes de Leon C.F., et al. Cholesterol and coronary heart disease mortality in elderly patients. J Am Med Assoc 1996, 275:110-111.
108. Foody J.M., Rathore S.S., Galusha D., et al. Hydroxymethylglutaryl-CoA reductase inhibitors in older persons with acute myocardial infarction: evidence for an age-statin interaction. J Am Geriatr Soc 2006, 54:421-430.
109. Robinson J.G., Booth B. Statin use and lipid levels in older adults: National Health and Nutrition Examination Survey, 2001 to 2006. J Clin Lipidol 2010, 4:483-490.
110. Zillich A.J., Garg J., Basu S., et al. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 2006, 48:219-224.
111. Alderman M.H. New onset diabetes during antihypertensive therapy. Am J Hypertens 2008, 21:493-499.